1,437,960 Shares in TriSalus Life Sciences, Inc. $TLSI Purchased by Wasatch Advisors LP

Wasatch Advisors LP acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the 1st quarter, HoldingsChannel reports. The institutional investor acquired 1,437,960 shares of the company’s stock, valued at approximately $5,752,000.

A number of other hedge funds also recently bought and sold shares of TLSI. Nantahala Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 1.5% in the fourth quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock worth $14,454,000 after buying an additional 30,582 shares during the period. Vanguard Group Inc. raised its holdings in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after acquiring an additional 345,186 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its position in shares of TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 35.5% in the 4th quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock valued at $5,245,000 after acquiring an additional 196,752 shares in the last quarter. Finally, State Street Corp boosted its stake in TriSalus Life Sciences by 37.4% in the 4th quarter. State Street Corp now owns 264,628 shares of the company’s stock worth $1,847,000 after purchasing an additional 71,995 shares during the period. 2.58% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Mats Wahlstrom purchased 60,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $2.53 per share, with a total value of $151,800.00. Following the purchase, the director directly owned 147,555 shares of the company’s stock, valued at approximately $373,314.15. This trade represents a 68.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael P. Stansky purchased 410,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The shares were purchased at an average price of $2.50 per share, with a total value of $1,025,000.00. Following the completion of the acquisition, the director owned 1,240,722 shares in the company, valued at $3,101,805. The trade was a 49.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 719,682 shares of company stock valued at $1,804,176 in the last three months. Insiders own 16.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on TLSI. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings cut TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Canaccord Genuity Group lowered their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Lake Street Capital dropped their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

TriSalus Life Sciences Trading Up 8.2%

Shares of NASDAQ:TLSI opened at $4.73 on Friday. The firm has a fifty day moving average of $3.87 and a two-hundred day moving average of $4.79. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The firm has a market capitalization of $290.52 million, a P/E ratio of -3.35 and a beta of 0.48.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.